Original regimen of subcutaneous interleukin 2 (IL2) and interferon alpha (IFN) in patients with metastatic renal cell carcinoma (MRCC) ineligible to receive intravenous (iv) IL2

被引：0
|
作者：
Escudier, B [1 ]
Rossi, JF [1 ]
Ravaud, A [1 ]
Savary, J [1 ]
Pignard, K [1 ]
Negrier, S [1 ]
机构：
[1] CTR LEON BERARD,FRANCH CANC CTR FEDERAT,CTR COORDINATING,IMMUNOTHERAPY GRP,F-69373 LYON,FRANCE
来源：
EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：470 / 470
页数：1
相关论文
共 50 条
  • [41] RECEPTOR MEDIATED ENDOCYTOSIS OF INTERLEUKIN-2 (IL2), AND DOWN-REGULATION OF SURFACE HIGH-AFFINITY RECEPTORS BY IL2 IN A HUMAN-TUMOR T-CELL LINE EVIDENCE THAT IL2 INCREASES THE RATE OF RECEPTOR ENDOCYTOSIS
    DUPREZ, V
    FERRER, M
    COMET, V
    DAUTRYVARSAT, A
    LYMPHOKINE RESEARCH, 1988, 7 (03): : 315 - 315
  • [42] Safety and efficacy of sequencing high-dose interleukin 2 (IL2) after tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma.
    Lam, E. T.
    Wong, M. K. K.
    Agarwal, N.
    Redman, B. G.
    Logan, T.
    Flaig, T. W.
    Monk, J. P.
    Jarkowski, A.
    Sendilnathan, A.
    Bolden, M.
    Kuzel, T.
    Olencki, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] IL1 AND TNF CONCENTRATIONS AS PREDICTIVE FACTORS OF CLINICAL-RESPONSE TO IL2 IN PATIENTS WITH RENAL-CELL CARCINOMA
    BLAY, JY
    COMBARET, V
    NEGRIER, S
    MERCATELLO, A
    FRANKS, CR
    PHILIP, T
    FAVROT, M
    FASEB JOURNAL, 1991, 5 (06): : A1772 - A1772
  • [44] Low-dose interleukin-2 (IL-2) in combination with interferon-A (IFN) and 5-fluorouracil (5-FU) for metastatic renal cell carcinoma (MRCC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 286 - 286
  • [45] INTERLEUKIN-2 (IL2) SYNERGIZES WITH GAMMA-INTERFERON (GAMMA-IFN) TO GENERATE LAK CELLS-INVITRO AND INVIVO
    MAZUMDER, A
    AGAH, R
    MALLOY, B
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 365 - 365
  • [46] Long-term disease- free survival (DFS) of metastatic melanoma (mM) and renal cell cancer (mRCC) patients following high-dose interleukin-2 (HD IL2)
    Clark, Joseph
    Curti, Brendan
    Davis, Elizabeth
    Kaufman, Howard
    Amin, Asim
    Alva, Ajjai
    Logan, Theodore
    Hauke, Ralph
    Miletello, Gerald
    Vaishampayan, Ulka
    Johnson, Douglas
    White, Richard
    Wiernik, Peter
    Dutcher, Janice
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [47] REGULATION OF GAMMA-INTERFERON (GAMMA-IFN) PRODUCTION OF INTERLEUKIN-2 (IL2) IN NORMALS AND PATIENTS WITH ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME
    FARMER, JL
    BENES, E
    BERTUCCI, D
    MONTGOMERY, A
    MORIN, G
    SMITH, R
    ALEXANDER, S
    GOTTLIEB, AA
    FEDERATION PROCEEDINGS, 1986, 45 (03) : 251 - 251
  • [48] NATURAL-KILLER CELL-FUNCTION AND MODULATION BY ALPHA-IFN AND IL2 IN AIDS PATIENTS AND PRODROMAL SUBJECTS
    LEW, F
    TSANG, P
    SOLOMON, S
    SELIKOFF, IJ
    BEKESI, JG
    JOURNAL OF CLINICAL & LABORATORY IMMUNOLOGY, 1984, 14 (03) : 115 - 121
  • [49] Activity of MVA 5T4 alone or in combination with either Interleukin-2 (IL-2), Interferon-alpha (IFN), or Sunitinib in patients (pts) with Metastatic Renal Cell Cancer (MRCC)
    Amato, R.
    Gary, A.
    Cao, A.
    Willis, J.
    McDonald, M.
    Naylor, S.
    Harrop, R.
    Shingler, W.
    Chikoti, P.
    Drury, N.
    EJC SUPPLEMENTS, 2006, 4 (12): : 39 - 39
  • [50] Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2)
    Parikh, Kinjal
    Stenehjem, David D.
    Sendilnathan, Arun
    Crispin, Hilda
    Van Atta, Joan
    Batten, Julia Anne
    Sageser, Daniel
    Grossmann, Kenneth F.
    Wang, Junfeng
    Samlowski, Wolfram E.
    Tantravahi, Srinivas Kiran
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
12345